Development and Validation of a Collagen Nomogram for Pretreatment Prediction of Pathological Complete Response in Rectal Cancer Patients

2021 ◽  
Author(s):  
Wei Jiang ◽  
Shijie Wang ◽  
Zhangyuanzhu Liu ◽  
Jixiang Zheng ◽  
Min Li ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Cancer Patients ◽  
Pathological Complete Response ◽  
Complete Response ◽  
Development And Validation

scholarly journals CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy

Diagnostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 516
Author(s):  
Daan Linders ◽  
Marion Deken ◽  
Maxime van der Valk ◽  
Willemieke Tummers ◽  
Shadhvi Bhairosingh ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Neoadjuvant Therapy ◽  
Cancer Patients ◽  
Pathological Complete Response ◽  
Neoadjuvant Treatment ◽  
Complete Response ◽  
Response Evaluation ◽  
Tumor Bed ◽  
Upar Expression ◽  
Diagnostic Biopsy

Rectal cancer patients with a complete response after neoadjuvant therapy can be monitored with a watch-and-wait strategy. However, regrowth rates indicate that identification of patients with a pathological complete response (pCR) remains challenging. Targeted near-infrared fluorescence endoscopy is a potential tool to improve response evaluation. Promising tumor targets include carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EpCAM), integrin αvβ6, and urokinase-type plasminogen activator receptor (uPAR). To investigate the applicability of these targets, we analyzed protein expression by immunohistochemistry and quantified these by a total immunostaining score (TIS) in tissue of rectal cancer patients with a pCR. CEA, EpCAM, αvβ6, and uPAR expression in the diagnostic biopsy was high (TIS > 6) in, respectively, 100%, 100%, 33%, and 46% of cases. CEA and EpCAM expressions were significantly higher in the diagnostic biopsy compared with the corresponding tumor bed (p < 0.01). CEA, EpCAM, αvβ6, and uPAR expressions were low (TIS < 6) in the tumor bed in, respectively, 93%, 95%, 85%, and 62.5% of cases. Immunohistochemical evaluation shows that CEA and EpCAM could be suitable targets for response evaluation after neoadjuvant treatment, since expression of these targets in the primary tumor bed is low compared with the diagnostic biopsy and adjacent pre-existent rectal mucosa in more than 90% of patients with a pCR.

PO-1094: Pathological complete response and outcomes in rectal cancer patients with treatment intensification

2020 ◽  
Vol 152 ◽  
pp. S579
Author(s):  
C. Rosa ◽  
M. Di Tommaso ◽  
L. Caravatta ◽  
M. Taraborrelli ◽  
D. Fasciolo ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Cancer Patients ◽  
Pathological Complete Response ◽  
Complete Response ◽  
Treatment Intensification

scholarly journals Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging

2011 ◽  
Vol 98 (1) ◽  
pp. 126-133 ◽  
Author(s):  
Ruud G.P.M. van Stiphout ◽  
Guido Lammering ◽  
Jeroen Buijsen ◽  
Marco H.M. Janssen ◽  
Maria Antonietta Gambacorta ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Predictive Model ◽  
Cancer Patients ◽  
Pathological Complete Response ◽  
External Validation ◽  
Complete Response ◽  
Ct Imaging ◽  
Pet Ct
Sign in / Sign up

Export Citation Format

Share Document